Cutaneous melanoma in situ: Translational evidence from a large population-based study

Oncologist

Volumn 16, Issue 6, 2011, Pages 896-903

  Mocellin, Simone ^a   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cutaneous melanoma; In situ; Incidence; Population study; Relative survival analysis; Risk; Treatment

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER INVASION; CANCER SURGERY; CANCER SURVIVAL; CUTANEOUS MELANOMA IN SITU; DIGESTIVE SYSTEM CANCER; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; POPULATION RESEARCH; POPULATION SIZE; PRIORITY JOURNAL; RISK REDUCTION; SKIN SURGERY;

AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SEER PROGRAM; SKIN NEOPLASMS; UNITED STATES;

EID: 79959626752     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0340     Document Type: Article

References (64)

1. MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009;20 Suppl 6:vi1-vi7.
2. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009;27:3-9.
3. StatBite: Distribution of melanoma incidence and mortality by age, 2001- 2005. J Natl Cancer Inst 2008;100:1498.
4. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687-701.
5. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
6. NCCN. Melanoma. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, 2009. Available at http://www.nccn.org/index.asp.
7. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009;9:587-595.
8. Ackerman AB. Malignant melanoma in situ: the flat, curable stage of malignant melanoma. Pathology 1985;17:298-300.
9. Clark WH Jr., Tucker MA. Problems with lesions related to the development of malignant melanoma: common nevi, dysplastic nevi, malignant melanoma in situ, and radial growth phase malignant melanoma. Hum Pathol 1998;29:8-14.
10. Elder DE, Jucovy PM, Tuthill RJ et al. The classification of malignant melanoma. Am J Dermatopathol 1980;2:315-320.
11. Clark WH Jr. Malignant melanoma in situ. Hum Pathol 1990;21:1197-1198.
12. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
13. Nelson JH Jr., Averette HE, Richart RM. Dysplasia, carcinoma in situ, and early invasive cervical carcinoma. CA Cancer J Clin 1984;34:306-327.
14. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006;355:51-65.
15. Gutkowicz-Krusin D, Rabinovitz HS. Kinetic model of progression of cutaneous melanoma population. Melanoma Res 2007;17:354-359.
16. Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 2005; 10:153-163.
17. Crowson AN, Magro CM, Sanchez-Carpintero I et al. The precursors of malignant melanoma. Recent Results Cancer Res 2002;160:75-84.
18. Tannous ZS, Lerner LH, Duncan LM et al. Progression to invasive melanoma from malignant melanoma in situ, lentigo maligna type. Hum Pathol 2000;31:705-708.
19. Dubow BE, Ackerman AB. Ideas in pathology. Malignant melanoma in situ: the evolution of a concept. Mod Pathol 1990;3:734-744.
20. Charles CA, Yee VS, Dusza SW et al. Variation in the diagnosis, treatment, and management of melanoma in situ: a survey of US dermatologists. Arch Dermatol 2005;141:723-729.
21. Megahed M, Schon M, Selimovic D et al. Reliability of diagnosis of melanoma in situ. Lancet 2002;359:1921-1922.
22. Pizzichetta MA, Argenziano G, Talamini R et al. Dermoscopic criteria for melanoma in situ are similar to those for early invasive melanoma. Cancer 2001;91:992-997.
23. Okamura JM, Barr RJ, Cantos KA. Benign atypical junctional melanocytic hyperplasia associated with intradermal nevi: a common finding that may be confused with melanoma in situ. Mod Pathol 2000;13:857-860.
24. Bartoli C, Bono A, Clemente C et al. Clinical diagnosis and therapy of cutaneous melanoma in situ. Cancer 1996;77:888-892.
25. Moller MG, Pappas-Politis E, Zager JS et al. Surgical management of mel-anoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol 2009;16:1526-1536.
26. Clark GS, Pappas-Politis EC, Cherpelis BS et al. Surgical management of melanoma in situ on chronically sun-damaged skin. Cancer Control 2008; 15:216-224.
27. Wolf IH, Cerroni L, Kodama K et al. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Derma-tol 2005;141:510-514.
28. Zalaudek I, Horn M, Richtig E et al. Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities. Br J Dermatol 2003;148:703-708.
29. Thorn M, Ponten F, Johansson AM et al. Rapid increase in diagnosis of cutaneous melanoma in situ in Sweden, 1968-1992. Cancer Detect Prev 1998;22:430-437.
30. Flotte TJ, Mihm MC Jr. Lentigo maligna and malignant melanoma in situ, lentigo maligna type. Hum Pathol 1999;30:533-536.
31. Wassberg C, Thorn M, Yuen J et al. Cancer risk in patients with earlier diagnosis of cutaneous melanoma in situ. Int J Cancer 1999;83:314-317.
32. Wagner RF Jr., Murphy CM. Risk classification of life and health insurance applicants with atypical melanocytic hyperplasia or malignant melanoma in situ. Cutis 1992;50:352-354.
33. McCaul KA, Fritschi L, Baade P et al. The incidence of second primary invasive melanoma in Queensland, 1982-2003. Cancer Causes Control 2008;19:451-458.
34. Francken AB, Shaw HM, Thompson JF. Detection of second primary cutaneous melanomas. Eur J Surg Oncol 2008;34:587-592.
35. Linos E, Swetter SM, Cockburn MG et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009;129:1666-1674.
36. Beddingfield FC 3rd. The melanoma epidemic: res ipsa loquitur. The Oncologist 2003;8:459-465.
37. Raziano RM, Clark GS, Cherpelis BS et al. Staged margin control techniques for surgical excision of lentigo maligna. G Ital Dermatol Venereol 2009;144:259-270.
38. Shumaker PR, Kelley B, Swann MH et al. Modified Mohs micrographic surgery for periocular melanoma and melanoma in situ: long-term experience at Scripps Clinic. Dermatol Surg 2009;35:1263-1270.
39. Dawn ME, Dawn AG, Miller SJ. Mohs surgery for the treatment of melanoma in situ: a review. Dermatol Surg 2007;33:395-402.
40. Powell AM, Robson AM, Russell-Jones R et al. Imiquimod and lentigo ma-ligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol 2009;160:994-998.
41. Hopson B, Richey D, Sajben FP. Treatment of lentigo maligna with imi-quimod 5% cream. J Drugs Dermatol 2007;6:1037-1040.
42. Woodmansee C, Pillow J, Skinner RB Jr. The role of topical immune response modifiers in skin cancer. Drugs 2006;66:1657-1664.
43. SEER. Surveillance Epidemiology and End Results. Bethesda, MD: National Cancer Institute, 2009. Available at http://seer.cancer.gov/.
44. SEER. SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2008 Sub (1973-2006 varying). Bethesda, MD: National Cancer Institute, 2009. Available at http://seer.cancer.gov/data/index.html.
45. SEER. Surveillance Research Program, SEER*Stat software. Bethesda, MD: National Cancer Institute, 2009. Available at http://seer.cancer.gov/seerstat/.
46. Levell NJ, Beattie CC, Shuster S et al. Melanoma epidemic: a midsummer night's dream? Br J Dermatol 2009;161:630-634.
47. Downing A, Newton-Bishop JA, Forman D. Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993-2003. Br J Cancer 2006;95:91-95.
48. Nevins T, Su Y, Doucette S et al. Incidence of cutaneous malignant melanoma in the Ottawa region: 1996 to 2006. J Cutan Med Surg 2008;12:276-281.
49. Chuang TY, Charles J, Reizner GT et al. Melanoma in Kauai, Hawaii, 1981-1990: the significance of in situ melanoma and the incidence trend. Int J Dermatol 1999;38:101-107.
50. Stratigos AJ, Katsambas AD. The value of screening in melanoma. Clin Dermatol 2009;27:10-25.
51. Halpern AC, Lieb JA. Early melanoma diagnosis: a success story that leaves room for improvement. Curr Opin Oncol 2007;19:109-115.
52. Janda M, Baade PD, Youl PH et al. The skin awareness study: promoting thorough skin self-examination for skin cancer among men 50 years or older. Contemp Clin Trials 2010;31:119-130.
53. Ajani J, Allgood V. Molecular mechanisms in cancer: what should clinicians know? Semin Oncol 2005;32:2-4.
54. Basil CF, Zhao Y, Zavaglia K et al. Common cancer biomarkers. Cancer Res 2006;66:2953-2961.
55. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-799.
56. Downing A, Yu XQ, Newton-Bishop J et al. Trends in prognostic factors and survival from cutaneous melanoma in Yorkshire, UK and New South Wales, Australia between 1993 and 2003. Int J Cancer 2008;123:861-866.
57. Criscione VD, Weinstock MA. Melanoma thickness trends in the United States, 1988-2006. J Invest Dermatol 2010;130:793-797.
58. Coory M, Baade P, Aitken J et al. Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002. Cancer Causes Control 2006;17:21-27.
59. Wolff T, Tai E, Miller T. Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150:194-198.
60. Terushkin V, Halpern AC. Melanoma early detection. Hematol Oncol Clin North Am 2009;23:481-500, viii.
61. Weinstock MA. Progress and prospects on melanoma: the way forward for early detection and reduced mortality. Clin Cancer Res 2006;12:2297s-2300s.
62. Strauss RM, Elliott F, Affleck P et al. A retrospective study addressed to understanding what predicts severe histological dysplasia/early melanoma in excised atypical melanocytic lesions. Br J Dermatol 2007;157:758-764.
63. McCalmont TH. Melanoma and melanoma in situ: build a better diagnosis through architecture. Semin Cutan Med Surg 1997;16:97-107.
64. Ruiter DJ, van Dijk MC, Ferrier CM. Current diagnostic problems in melanoma pathology. Semin Cutan Med Surg 2003;22:33-41.